Erschienen in:
02.10.2022 | ASO Author Reflections
ASO Author Reflections: The Current Insurance Authorization Process and Future Directions for Patients Undergoing Cytoreductive Surgery and HIPEC
verfasst von:
Cecilia T. Ong, MD, Oliver S. Eng, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 1/2023
Einloggen, um Zugang zu erhalten
Excerpt
Indications for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) exist across multiple histologies, leading to an expansion in the number of health systems providing this care. Insurance coverage and payer mix have been demonstrated to impact access to care, clinical outcomes, and financial ramifications following CRS/HIPEC,
1,2 but the influence of the insurance authorization process has not been well characterized. We sought to characterize this process from the perspective of a large tertiary referral center to identify roadblocks to authorization and barriers to claim reimbursement. …